Article
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.
Antiviral therapy - 1 Jan 2018
Wyles David, Mangia Alessandra, Cheng Wendy, Shafran Stephen, Schwabe Christian, Ouyang Wen, Hedskog Charlotte, McNally John, Brainard Diana M, Doehle Brian P, Svarovskaia Evguenia, Miller Michael D, Mo Hongmei, Dvory-Sobol Hadas
Abstract excerpt
BACKGROUND: Data on persistence of NS5A resistance-associated substitutions (RASs) may have implications for resistance testing approaches and selection of initial and retreatment strategies. METHODS: Long-term persistence of NS5A RASs in HCV genotype (GT) 1 infected subjects (n=76) who did not achieve sustained virological response after receiving ledipasvir (LDV) without sofosbuvir (SOF) and were subsequently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.